Heat Biologics Stock Price - HTBX

Best deals to access real time data!
Canadian Level 1 + USA
Monthly Subscription
for only
CHART Trader
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Heat Biologics Inc HTBX NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.014 -3.06% 0.4439 0.4601 0.44 0.44 0.4579 20:00:00
Bid Price Ask Price Spread Spread % News
0.44 0.525 0.085 16.19% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
311 148,575 $ 0.4472197 $ 66,446 520,938 0.35 - 1.86
Last Trade Time Type Quantity Stock Price Currency
17:13:39 1 $ 0.44 USD

Heat Biologics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 15.16M 34.14M $ -15.73M -1.28 - 31.72M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Heat Biologics News

Loading Messages....

Latest HTBX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HTBX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.44140.48830.430.469732129,2330.00250.57%
1 Month0.430.630.400.4922061403,2050.01393.23%
3 Months0.5920.650.350.4831499320,495-0.1481-25.02%
6 Months0.72330.83580.350.5439274255,246-0.2794-38.63%
1 Year1.351.860.351.01381,278-0.9061-67.12%
3 Years8.4012.500.354.17621,796-7.96-94.72%
5 Years39.001109.000.359.23633,771-38.56-98.86%

Heat Biologics Description

Heat Biologics Inc is a US-based immuno-oncology company. It is engaged in developing therapies which activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT), form the basis of its product candidates. Through ImPACT, it developed product candidates consisting of live, genetically-modified, irradiated human cancer cells which secrete tumor-associated antigens together with an immune response stimulator called gp96. Through ComPACT, the firm engineered product candidates that incorporate ligand fusion proteins targeting co-stimulatory receptors into the gp96-Ig expression vector.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.